Document is current
Any future updates will be listed below
-
Authors
Braido, Fulvio
Bonini, Matteo
Castellani, Walter
Comel, Andrea Claudio
Lombardo, Francesco Paolo
Spanevello, Antonio
Vatrella, Alessandro
Contoli, Marco
-
Funding
Funding for this research was provided by:
Chiesi Farmaceutici
Edge Consulting
- License Information
-
More Information
Article History
Received: 15 May 2025
Accepted: 16 July 2025
First Online: 4 August 2025
Declarations
:
: Matteo Bonini has received research grants, advisory board honoraria, consultancy fees, and lecture fees from AstraZeneca, Chiesi Farmaceutici, Grifols, GlaxoSmithKline, Lallemand Health Solutions, Lusofarmaco, Menarini Group, Omron Healthcare, and Sanofi. Francesco Paolo Lombardo has received consultancy and lecture fees from Chiesi Farmaceutici, GlaxoSmithKline, and AstraZeneca. Walter Castellani, Marco Contoli, Andrea Claudio Comel, Fulvio Braido, Antonio Spanevello, and Alessandro Vatrella have nothing to disclose.
: The survey was conducted in accordance with the principles outlined in the Declaration of Helsinki, and informed consent was obtained from patients prior to their involvement. Ethics approval was not required for this study as it was based on a voluntary, anonymous survey of healthcare professionals and patients, without the collection of sensitive personal data or interventions affecting patient care, in accordance with applicable ethical guidelines and regulations.
